Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2308-2313

  Yasuda, Satoshi ^a,f   Sawano, Hirotaka ^b   Hazui, Hiroshi ^c   Ukai, Isao ^d   Yokoyama, Hiroyuki ^a   Ohashi, Junko ^a,f   Sase, Kazuhiro ^e   Kada, Akiko ^a   Nonogi, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b SAISEIKAI SENRI HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced life support; Anti arrhythmic drugs therapy; Cardiac arrest; Defibrillation; Ventricular fibrillation

Indexed keywords

ADRENALIN; NIFEKALANT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; EXTRACORPOREAL OXYGENATION; FEASIBILITY STUDY; FEMALE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; JAPAN; JAPANESE; MALE; MULTICENTER STUDY; RESUSCITATION; THERAPY RESISTANCE; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEASIBILITY STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OUT-OF-HOSPITAL CARDIAC ARREST; PATIENT ADMISSION; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINONES; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TORSADES DE POINTES; TREATMENT FAILURE; VENTRICULAR FIBRILLATION;

EID: 78349241414     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0759     Document Type: Article

References (24)

1. Nichol G, Rumsfeld J, Eigel B, Abella BS, Labarthe D, Hong Y, et al. Essential features of designating out-of-hospital cardiac arrest as a reportable event: A scientific statement from the American Heart Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, Perioperative, and Critical Care; Council on Cardiovascular Nursing; Council on Clinical Cardiology; and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2008; 117: 2299-2308.
2. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resuscitation after out-ofhospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341: 871-878.
3. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346: 884-890.
4. Ishii M, Kamiya J, Hashimoto K. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent. Drug Dev Res 1995; 35: 61-68.
5. Oyabe H, Sano H. Pharmacological and clinical profile of nifekalant (shinbit(R) injection), a class III antiarrhythmic drug. Folia Pharmacol Jpn 2003; 119: 103-109.
6. Ohashi J, Yasuda S, Miyazaki S, Shimizu W, Morii I, Kurita T, et al. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride. J Cardiovasc Pharmacol 2006; 48: 274-279.
7. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, et al. Efect of MS-551, a new class III antiarrhythmic drug on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23: 674-680.
8. Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new Class III agent: Comparison with dl-sotalol in dogs. J Pharmacol Exp Ther 1998; 285: 687-694.
9. Sugiyama A, Satoh Y, Hashimoto K. Acute electropharmacological effects of intravenously administerd amiodarone assessed in the In Vivo canine model. Jpn J Pharmacol 2001; 87: 74-82.
10. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
11. Huang J, Skinner JL, Rogers JM, Smith WM, Holman WL, Ideker RE. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol 2002; 40: 375-383.
12. Guidelines 2005 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: Section 3: Management of Symptomatic Bradycardia and Tachycardia. The American Heart Association in collaboration with the international liaison committee on resuscitation. Circulation 2005; 112: 67-77.
13. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J 2005; 26: 2185-2192.
14. Iwami T, Kawamura T, Hiraide A, Berg RA, Hayashi Y, Nishiuchi T, et al. Effectiveness of bystander-initiated cardiac-only resuscitation for patients with out-of-hospital cardiac arrest. Circulation 2007; 116: 2900-2907.
15. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, et al. Comparison of nifekalant and lidocaine for the treatment of shockrefractory ventricular fibrillation. Circ J 2006; 70: 442-446.
16. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025-2034.
17. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J 2009; 73: 2021-2028.
18. Yoshioka K, Amino M, Morita S, Nakagawa Y, Usui K, Sugimoto A, et al. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)?: Comparative study of out-ofhospital CPA with acidosis and in-hospital CPA without acidosis. Circ J 2006; 70: 21-27.
19. Cheng JH, Kodama I. Two components of delayed rectifier K+ current in heart: Molecular basis, functional diversity, and contribution to repolarization. Acta Pharmacol 2004; 25: 137-145.
20. Jackson RE, Freeman SB. Hemodynamics of cardiac massage. Emerg Med Clin North Am 1983; 1: 501-513.
21. Chen YS, Lin JW, Yu HY, Ko WJ, Jerng JS, Chang WT, et al. Cardiopulmonary resuscitation with assisted extracorporeal lifesupport versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: An observational study and propensity analysis. Lancet 2008; 372: 554-561.
22. Aoyama N, Imai H, Kono K, Kato S, Fukuda N, Kurosawa T, et al. Patient selection and therapeutic strategy for emergency percutaneous cardiopulmonary system in cardiopulmonary arrest patients. Circ J 2009; 73: 1416-1422.
23. Takeuchi I, Takehana H, Satoh D, Fukaya H, Tamura Y, Nishi M, et al. Effect of hypothermia therapy after outpatient cardiac arrest due to ventricular fibrillation. Circ J 2009; 73: 1877-1880.
24. Hanada H, Okumura K. From 4-links to 5-links of "chain of survival". Post-resuscitation care is critical for good neurological recovery. Circ J 2009; 73: 1797-1798.